Omda AS (OMDA) Earnings Call Transcript
August 27, 2026
Earnings Call Speaker Segments
Good morning, and welcome to Omda's presentation of the results for Q2 2026. Two important themes are on the agenda today. Those are the mission criticality of the software platforms we offer and the predictable nature of this business. I'm Sverre, Omda's CEO, and as usual my colleague and CFO, Einar, is sitting beside me, mainly to ensure I don't get too optimistic. Today we'll be discussing two important things in our business. It's the split between Specialized Healthcare and Emergency. That split is vital for understanding Omda's business in the years ahead. We divide this business into those two, and I think we should start by having Einar explain the rock and roll version of our numbers for the second quarter. Einar.
Thanks, Sverre. Overall the figures: revenue came in at 127 million Norwegian kroner, an EBITDA margin of 25%, and organic growth of 9% quarter over quarter. All in all, strong, strong figures. Emergency accounts for 44% of total revenue, while Specialized Healthcare, our other main market, makes up 56%. You'll notice somewhat stronger figures in Specialized Healthcare than in Emergency. That's just the normal quarter-to-quarter and year-to-year variation. On the whole, strong figures. We'll get into the details a bit later. Stay tuned.
All right, so let me walk through the basics of those two market segments. Specialized Healthcare is what Omda was built on 20 years ago. To give a quick rundown of the five areas there: Woman and Child covers pregnancy, birth, and the follow-up afterward. That's also a value chain — a software platform whose various components handle different tasks across highly critical parts of birth and woman and child healthcare. Then over on the right-hand side, we have something similar, though entirely different where Medication Management and Cancer are concerned. That too consists of value chains and software platforms serving distinct user groups and the steps connecting them. Naturally, should you get cancer — and I hope you don't — you'd want the best possible medication treatment. Functions for designing and calculating the cure, for delivering it to you, for producing it correctly in the pharmacy, and also for getting back to administering it with the nurse, and then, naturally, the follow-up from oncologists plus your own app for tracking things as well. That's the typical similarity shared by these platforms, though they're entirely different, naturally, in terms of what each does for you as a patient. Then in the bottom left corner we have so-called Connected Imaging, which is likewise a combination of complex platforms.
First, there's infrastructure for sharing images across regions and even within a single country. Then, at the top, in a similar way, you have the highly specialized component, for example in Cardiology or skin cancer. Every one of those areas carries its own specialties. Then in the middle sits LIMS or blood management. That, of course, is also a critical item for hospitals. Blood and cells and tissue get collected from the citizens. You need to handle it, store it, and so on, and then of course deliver these products to patients in critical situations at the specialized hospitals. That too is a typical 50-year-old business with long-term market leadership here in the Nordics. Then there's Health Analytics, which is, of course, a different matter when it comes to processing. On the other hand, the data matters critically: critical to researchers, critical to managing even national registers, making sure you have the overview and the ability to use that data to run your business. All of these form part of what we call Specialized Healthcare. I think that's very important for you when you look at our numbers and at the development and the predictability of the business — that this is what it's all about, critical for everyone.
In a similar way, Emergency is another critical area for us — our other leg, so to speak. To walk through that value chain, we'll begin at the upper left: planning and preparedness. What does that mean? Naturally, any society has services that people depend on — a 911 call, for example. You need to plan for what kinds of resources are actually available to assist you. There's also software designed to analyze this and to plan it properly. For example, when it's the 17th of May in Norway or the 4th of July in the US, that kind of event naturally presents a different planning situation than other days of the week. Moving to the left, down toward the lower left, you'll notice that the most important part, naturally, when someone calls in is that the operator assisting them actually has the tools and the capability to decide quickly and to distribute and dispatch the correct resource at the right time. Naturally, when you look at the on-scene response, what does that mean? In the on-scene response, typically, you have one of three kinds of resources. It could be the healthcare part, the fire, or the police, or sometimes — or often, in fact — it's all of them.
Take, for example, a larger-scale incident. So it matters across the value chain to have components capable of handling every one of those situations. Next comes transport and care. Inside an ambulance, there are two groups of users. The driver needs to reach the correct location as quickly as possible. And then, naturally, in the rear of the vehicle, there's the capacity to log and manage critical information, so that once you arrive at the corner on the right-hand side and enter the hospital's emergency room, those receiving the patient are prepared and can truly assist in the best possible manner. And then, once more, at the top right, you'll notice that the data from all these steps gets used again to return to the start — planning and preparedness. This level of quality matters greatly to society. We're in many countries with this. Following the acquisition of Saab Public Safety Solutions, we have, naturally, reinforced this value chain enormously. Probably among the most significant things regarding what we've now accomplished through the second quarter 2026 in our business is the added strength of the platform here — a platform of long-term importance for customers.
And beyond that, when you look at what is happening in the market, earlier we had significant national and regional deployments of these platforms. One example is SOS Alarm in Sweden. A second regional example is Valencia in Spain. Those two operations handle millions of calls each year, and they are, of course, critical infrastructure. We also have other countries such as Greece, Moldova, Croatia, Slovakia, and Montenegro. In the second quarter of 2026, with the signing related to the acquisition of Saab Public Safety Solutions, we have raised the annual sales for next year in the UK from 2% to 15% of our business. That matters too, because the regional customers and even national entities we serve there are just as critical as many others, and it gives us plenty of opportunities to bring our added platform software components to existing customers and new customers. Overall, for this quarter, probably the biggest highlight, aside from our predictable business, is the fact that we completed this acquisition. Now, Einar, it is time to go through the numbers.
Thanks, Sverre. Now let's go through the figures and get into the specifics. As I mentioned, revenue as reported for the second quarter came in at 127 million NOK. That's organic growth of 9% and reported growth of 5%. For anyone puzzling over why those differ, we faced FX headwinds during this quarter. Most of you will note that the Norwegian krone appreciated against nearly every currency in which we trade. About 85% of our sales come in currencies other than the Norwegian krone, so currency swings affect us just as much. On profitability, a sharp rise compared with the second quarter of last year — 23 million in that quarter, and 32 million in this one — with the EBITDA margin climbing from 19% to 25%. Perhaps more significant still, I should note that capex fell to roughly 7% this year, which gives us a cash EBITDA of 18% against 9% last year. We truly are moving in the right direction, at about the pace we had anticipated. Earnings quality stays strong: recurring revenue at 97% on a reported basis, and software accounts for 76% of that recurring revenue. Professional services are back on track this quarter — somewhat weak in the first quarter of this year, but back on track now.
And once more, on professional services: those are largely recurring as well — we figure roughly 90% of professional services really do recur. It comes down to predictability, and why is our business so predictable, Sverre? Could you walk us through a few examples of that?
Certainly. That's essential for grasping Omda. When you consider the platforms and how critical they are, the entire architecture of these systems plays a very, very significant role in society. Mission-critical daily operations are managed through them every day and every second. They're also certified — that's part of what defines the quality of each operation. That's likewise why customers have neither the ability nor the desire to alter things. They're keen to build new things, but not to change these. This public sector customer base naturally relies on us, and that's a substantial responsibility for us. Switching these systems isn't something they want, since it wouldn't make good business sense for society. Embedded by design genuinely describes how these platforms stand for the customer. And of course it isn't just the technical side of the systems — it's also the relationship built with these customers over decades. Those long customer relationships exist because the critical platforms serve the customers, who depend on them, and it's a major responsibility for us to manage these systems and work alongside the customers to keep modernizing them as well, delivering new components through the years that support the value chains.
That's what generates organic growth that is repeatable and profitable. It's essential to how we view the upcoming steps on our path forward. And when we discuss recurring revenues, that means not just software recurring revenues—it also covers the recurring, or repeatable, business in terms of dependencies on our services. Take, for example, the assistance we must provide with training, integrations, and other service types that support customers on an ongoing basis. Two principal markets hold our focus: Specialized Healthcare and Emergency. Both of them—and the result of that approach—are how we arrive at this highly predictable business that we have. Such predictability, Einar, isn't just about the second quarter and the quarters ahead; it also extends to predictability over the long term. Perhaps you could then concentrate on discussing the future and our guidance.
Looking ahead, that's where our focus is. On M&A — the true driver of growth here at Omda — we're trying to show what 2026 will look like, both the organic expansion and the growth from acquisitions. These are pro forma figures. As we mentioned, with the Saab Safe transaction, the continuing business is performing somewhat better than we initially expected. The 2026 bar shows what things would look like had we owned Saab Safe for the entire year. That brings us to approximately 600 million Norwegian kroner in sales. We'll add that, and it becomes the new base as we head into 2027. Then we expect to keep making acquisitions. When we announced the Saab deal, we noted it was our first M&A announcement this year — though not necessarily our last. I believe I can say that again. M&A and profitable growth will remain our focus as we seek out opportunities. Meanwhile, for the existing business, our guidance stays at a 28% to 32% EBITDA margin, though keep in mind we stated that capex will decline from 10% of total sales to 5% of total sales.
When we look beyond that, this isn't just a question of 2026 and 2027 — it's also about our position five years from now. Let us restate what we've said: on the organic side, we still expect growth of 5% to 10%, and inorganic growth — meaning growth achieved through acquisitions — of 10% to 20% of our base. That's what we keep seeing ahead of us. Our pipeline of potential transactions is large. Once again, we build value chains the industrial way. There are plenty of opportunities out there, and we're out hunting for them. There's no question about that. Okay. Saab — that deal, that acquisition, is genuinely transformative for us, Sverre. Perhaps you could walk us through the details of what exactly it means? What does it change?
That matters, I believe. As I said, the biggest event during our second quarter. As I said, the UK public sector is turning into a highly, highly significant portion of our business. We're also building a wider platform that we already had in place beforehand, and it's becoming among the strongest in Europe for a full value chain across the entire emergency ecosystem. We're bringing on more than 75 people who have been working — lots of them for many, many years — on building this very strong platform known as SAFE, and the SAFE products we acquire there, together with that expertise, will make us far, far, far stronger. We anticipate closing this soon, in the fourth quarter. Up to that point, Saab is operating the business, though we expect the closing to go ahead as planned. Then, of course, most importantly, for you to consider what's happening in '26, '27 and the years ahead, the latest evidence from this acquisition — which matters — is that further contracts with customers have been signed, 60 million SEK recently, and that shifts our outlook for the ongoing business in 2027, rising much more than what we published back in June when the acquisition was announced.
We now believe the projected yearly revenue base is going to exceed 100 million. And being able to cross-sell across our existing business, plus bringing our people together inside one business unit, will generate a lot for us that matters when it comes to profitability and growth. Beyond this acquisition, something else that matters for our profitability is, naturally, the current AI situation, which represents a great opportunity for Omda. You need to be careful with AI and apply it responsibly. Still, there is plenty we can do. On top of that, as I have explained in detail, you see that we deliver these certified software components that are mission-critical. That means nothing will happen on the customer side. When it comes to AI use, not much is going to change, apart from added functionality somewhere when customers want it. For us, the most important thing will be the development cycles: testing, documentation, and so on — the efficiency, the capacity to work far more effectively, is there. We see that 12 months ago, a few programmers used AI tools. Today, everyone does.
So what we're doing at this point is, naturally, building out a platform — one that spans the whole group — which ensures we can handle all of these security mechanisms, the cost-effectiveness of using AI, and so on. From our side, it's a very structured approach to AI. What you saw in the second quarter is software investment running slightly below the guidance we gave. I think that gives you a taste of what will happen as AI gets used here by our people in Omda, because across all the processes underway, there are plenty where AI plays a part — particularly in areas like testing and documentation, which becomes simpler and more efficient. Then, naturally, as Einar mentioned, our ambition here is to also deploy AI to safeguard the trend we've publicly guided on, namely cutting capex from 10% to 5%. AI forms part of how we allocate capital. Einar, speaking of capital allocation, perhaps you could say a bit more about other forms of capital allocation.
When it comes to capital allocation, the goal is to deploy funds where they generate the greatest value while also maintaining capital. On that note, we've seen that bond financing conditions in the market look appealing, and Omda 02 Pro is currently trading well. We watch that market very closely, keep monitoring it, and assess refinancing options. Cheaper interest cost is naturally appealing for us. That would boost return on investment as well as return on capital employed and return on equity. The investments we pursue remain focused on targeted acquisitions, add-ons to customers, bolt-ons, and AI-enabled productivity. Overall, capital allocation at Omda comes down to build or buy. Either we build something, which means capex, or we purchase something. Quite often we do the latter, since buying something brings customers with it and brings income with it. The entire theme here is discipline. Sverre.
What we're discussing here is, of course, also about looking ahead. As you'll notice, our forward plan naturally centers on the organic growth we already have. Over the past 10 years, it has ranged between 5% and 10%, occasionally a bit higher and occasionally a bit lower, but on average, that's what will also occur over the next 10 years. We've stated that 10% to percent 10% 20% per year regarding acquisitions is what we aim for. We've also observed, and you've likely observed too, and Einar will explain this as well, that the steady rise in EBITDA during the second quarters over the last three years is, of course, meant to reach an average of 30% and above over time. What we're doing now is, of course, concentrating on the activities around cutting capex, the capital allocation regarding our own software, and not halting innovation — quite the reverse. We believe we'll innovate faster and better using the new tools and a responsible use of the new platforms. Then, of course, our portfolio — it matters greatly to all of you who are modeling our future over the next 5 to 10 years — that the emphasis we place on Emergency and Specialized Healthcare is what generates this predictability and the capacity to plan properly across years.
Naturally, we’ll stick with the decentralized approach we’ve had, in which each business unit leader tracks cash flow and cash EBITDA for every unit on a daily basis—that also lets us grow cash from operations. Einar, could you walk through what has occurred across the quarters in recent years and tell us where we’re going?
Right. So where are we going? That's a fair question. One thing to remember: Omda isn't truly a quarterly business, so you need to focus on the bigger trend. We're here for the long haul. If you just take those three quarters — Q2 '24, Q2 '25 and Q2 '26 — the trend is extremely clear. There's no doubt about the direction. On the left you see the EBITDA bar, on the right, within the groups, the cash EBITDA bar. We go from a 10% EBITDA margin in the second quarter of 2024, to 19% in '25, to 25% this year. The direction is unmistakable. Then cash EBITDA, meaning capex, we had 0 cash EBITDA in '24, 9% in '25 and 18% in 2026. That trend is very clear too, and we expect it to carry on. As we said, our guidance is 28% to 32%, and we said capex should come down from 10% to 5% over the years. That's the direction we're moving in, and we're making solid progress. To sum up, what does Q bring to the Omda story? Highly predictable and profitable organic development. A transformational Saab business — the acquisition has been signed.
That genuinely transforms what we are once more — from a Norwegian business into a Nordic one, and from a Nordic business into an international, European one. In our view, the UK remains part of Europe. A very clear portfolio sits at the center, focused on 2 main markets: Specialized Healthcare and Emergency. We keep exploring what AI can do, and it's also a key driver for reducing capex, boosting productivity, and bringing new initiatives to market. The 2026 guidance, that's being reiterated again. Keep in mind, currency has given us some headwinds — you can see we still guide between 500 and 525, though likely toward the lower end of that range given the FX headwinds, but that's the only factor. FX, I just want to note, does affect the top line, yet to a big extent we have a natural hedge because much of the cost remains in those same currencies. It isn't a perfect hedge, but it's a solid one. On the margin in percent terms, the impact is very small. Okay. What's in front of us? For operations, in one word — actually 2 — Kaizen, which means continuous improvement. We'll keep concentrating on organic growth and the opportunities there, and we'll keep seeking areas on the cost side where costs can be improved to lift the margin.
Genuine expansion is achieved by way of targeted M&A. Deals are originated in-house. Relationships get built and nurtured across a great many years, and we act once our criteria are satisfied and a reasonable agreement can be reached that works for everyone involved. So if you're an investor seeking a sound place to put money, or an entrepreneur wanting a stronger home for your business, Omda welcomes you. SaaS and software are not the whole of what we do. We provide vital infrastructure to society. All right. That's all from me. Let's go to Q&A and find out what's there. A few questions have come in already. As we get to them, keep typing your questions and we'll handle them. The initial one is written in Norwegian, sent in by KMD. I'll put it into English. "Congrats on the strong figures." Thanks. "At what point do you anticipate capitalized development to fall to 5%?" We've stated that we were at 10% last year, and we've said that step by step across a five-year span, we would trim it by 1 percentage point annually. For this year, our guidance is 9%; the following year ought to be 8%, and so on. During the second quarter, as you can see, we actually came in slightly under that.
We're not claiming that 7% applies to this year, but it's definitely an indication of what's ahead. This one's for you, Sverre. It concerns public tenders. The question reads, "Could you please comment on how well Omda does on public tenders? For instance, I noticed Frequentis won the NKS110 over Omda, though there were also some wins in Sweden, for example, with Dermicus."
First, when it comes to tenders, our main route to growth in this market is buying systems that have been part of an infrastructure for many, many years, and then the organic growth from Omda in our budget for, say, '26 and '27 rests on additional sales to existing customers. That's the core strategy. So yes, we do sometimes take part in tenders, but we don't primarily gauge our business by them. The reason is that in the kind of business we're in, most of our software platforms and systems are there for many, many years and decades. So tendering is a few. There are examples. A couple of years ago, we won this national tender for blood management in Denmark. We have won additional contracts during the year, for instance, also here in Stockholm on blood management. There are examples, but sometimes years pass between them. I think the main answer to that question is that our main focus in the business is not winning tenders, and we don't measure tenders as such. We normally take part in tenders when it's very relevant to some of our customers and they want us to participate.
That will keep being the core approach for us.
Thank you, Sverre. There are six additional questions still in the queue, so feel free to keep typing in more if you have them. Here's one from Javier, and it's a straightforward one. "Is Omda spelled with a name or with capital letters?" The first one is Omda. It isn't an abbreviation of any kind; it's Omda, capital O and small m-d-a. A question from Hjalmar on LIMS and blood management is coming up, along with the margin and development there, because obviously, when you look at the breakdown per business area, you see a huge difference there in the businesses. Some have strong organic growth, some have less, more modest organic growth, some have used a lot of capex, some don't have any capex at all. This is an observation on LIMS. The question is, "LIMS has run with a very thin EBITDA minus capex margin, EBITDAC, for a long time, with capex near 20% of segment revenue. Can you give some color on this? Why is that? Growth is obviously strong, I assume it's still in an investment phase. What is normal EBITDA minus capex?"
That is a really solid question, and beyond just asking something, it also delivers a conclusion regarding the investment phase. This business's earliest customers arrived in the mid-'60s, so it carries many decades of history behind it, and many decades lie ahead as well in terms of collaboration as a leading software platform for critical blood management in the Nordics and with customers outside as well. Sure, looking at the short term — and short term here means, for example, the national contract I brought up with Denmark. Even though they have had a system running in production for over a decade, what they are building is a national platform instead of a regional one. That process in itself takes multiple years, roughly a five-year undertaking. Across those five years, naturally, the business must also put investment into software and operate differently in how it handles its ordinary customers. Put simply, the answer is yes — it remains, as planned, within an investment phase, and the ordinary business should, of course, as we have stated as an ordinary KPI, deliver at least 30% EBITDA and at least 20% cash EBITDA. Given its history and its leadership position in the Nordics, I believe this business will also carry the potential to expand considerably further beyond that over the years ahead.
Thank you, Sverre. A few finance-related questions have come in, and I'll handle those personally. One concerns cash, and it goes, "Good morning." Morning to you as well. "By year-end, how do you anticipate that cash position will develop? Do you foresee any need to draw on external financing sources?" To start, as ever, the net working capital profile included in our report shows that we consistently hold plenty of cash at year-end while running leaner during the third quarter and the start of the fourth quarter. That pattern, in all likelihood, will persist. With that said, you'll note that cash from operations and cash conversion are strong. We observe cash EBITDA moving from 0 to 9 to 18 across '24 to '26, so our cash position is strengthening. What that means is that for operational purposes, there's no requirement to draw on external financing sources. External financing sources come into play with M&A—any acquisitions that justify drawing on external financing sources, naturally, subject to size. Looking a few years out, we'll find that we should increasingly be in a position to fund even smaller bolt-ons on our own.
I'll pick up with a follow-up question on that same topic, net debt. "Hi. For '26 and '27, what net debt/EBITDA ratio do you expect?" During the first quarter we presented a chart, and we did so in connection with Saab as well. Again, on net debt to EBITDA, we're aiming for roughly 3. It might run slightly higher for a brief stretch, or slightly lower, but being at 5 to 6 is clearly not where we want to be. We're moving toward investment grade — at present we're probably in what we refer to as the crossover segment. Now, Sverre, there are a question, or really two questions, about professional services, concerning how predictable professional services is and how much of total income it makes up, and so on. They come from Hjalmar, and here's the first one first: "In '25 and '26, professional services grew quickly, well above recurring revenue. Going into 2027 and beyond, how recurring and sustainable is that? Is it driven by milestones with tough competition ahead, or is it genuinely recurring, and why can it grow so much faster than recurring? Explain the beast."
That's a solid question, and I'd say it matters a lot if you want to grasp which portion of this business is repeatable. When we refer to professional services, we aren't selling professional services or entering tenders, for example, in an effort to sell our services. That isn't our model. Still, since these platform products are predictable, mission-critical and multi-number, customers naturally rely on particular services at the same time. The growth you've observed there will keep going, with the usual 5% to 10% growth as seen previously. What separates the last couple of years from earlier ones, I'd say, is that we were going through a certain transition. We decentralized, and so on, which makes comparison hard. That said, I believe '25 and '26 will also repeat into '27 and '28, with a portion of our professional services staying strong. I'd also add that about 90% of those professional services is a kind of repeatable business, since the same customers from years back are the ones buying new services. A few things make up the lumpy portion of professional services.
Naturally, at the top of the list would be the periods when we concentrate, say, during Q1 and Q2, heavily on AI—assigning our in-house specialists, who customers typically ask for, to work within Omda so that development of our AI platforms moves faster, for example. Things of that kind do take place, yet as for the remaining portion—90% of it—my view is that you ought to regard it as a business growing steadily at 5% to 10% in the years ahead as well.
Thanks, Sverre. We also have a follow-up from Hjalmar. He asks: "Professional services were actually soft in Q1, but your guidance for the full year suggests that segment needs to grow substantially over the remainder of 2026. How would you explain that bridge — how do you close that gap?"
Yes, that's right. As I said, in the first quarter a great many of our key senior people were focused on, obviously, the AI setup, since AI arrived quickly. I'd say we've been engaged with AI for many years, but being able to use the tools to genuinely build something great for our developers — the new tools that emerged just 6, 7 months ago have changed that. The first quarter is clearly a deliberate approach internally. We still have some of it, but yes, we believe professional services in the second half will also be strong, and that our current guidance of 500 to 525 — and of course, as Einar mentioned, there are some FX here — but we stick to that guiding, including professional services.
Thanks. There was another question that came in from Hjalmar as well, about LIMS and the project. He asks: "When the Danish project wraps up, will that raise recurring revenue? Since a big portion of LIMS revenue today appears to be project-based — which means a lot of professional services — shouldn't that revenue fall off once those projects are done? What comes next after we take Denmark?"
The quality of income—if that's the way to put it—always differs, depending on how much comes from professional services versus recurring revenue. And yes, Denmark isn't the only place this applies to. Keep in mind that LIMS has a 50-year history, and the platform connecting user groups across all these Nordic regions—they've been collaborating, and all those granular details involving thousands of fields that handle critical information and procedures will, of course, boost recurring revenue once every customer has moved onto our new platform and new versions. Right, the share of recurring revenue is going to rise relative to professional service in that business as the years go by. That said, we have time to plan, because this is a long-term business—no need to fret quarter to quarter. It's a crystal clear plan with 50 years of history behind it. Unfortunately, I won't be alive in 50 years, I'm sorry to say, but LIMS will certainly still be around.
On that note, what's the status of LIMS? Is it just Denmark, or is it broader?
No — LIMS is arguably the leading business across the Nordics. In Sweden you'll find it holds 100% of the market, and since it's the national solution in Denmark, it's 100% there as well. In Norway it accounts for over half, including the key institutions, and even in Iceland — plus we have the ability to export it. Looking at the existing business, and to return to the tender question, we aren't counting on extra tenders to support the model we've laid out here for the coming years, in terms of 5% to 10% organic growth and 30%-plus on the EBITDA side. Given our strong Nordic position, it's fair to say that if you're talking specifically about LIMS, this is a classic, highly specialized healthcare-type platform that is mission-critical — if it went down, it would affect many other operations within hospitals, such as surgery and so on. It has to function, it's critical, and on our side it's profitable.
Thanks for that, Sverre. We have a question here regarding the acquisition of Saab Public Safety. The question reads, "Could you please explain how the new Saab acquisition can be utilized within the existing operations and existing clients, i.e., synergies? Has cross-selling been the case in earlier acquisitions? How does this work and why is it possible? Why can we do any cross-sale? How does this work within Omda?"
Yes, on cross-selling — when we discuss cross-selling, it matters to grasp that if you look at Specialized Healthcare, where you've got various types of disciplines, medical disciplines, cross-selling between them doesn't apply. But inside Emergency, when you consider the full value chain and the ecosystems of components, you'll notice that the steps I brought up regarding planning, analytics, for instance — to give a concrete example, when we have all our customers, even in the UK, we have many customers using these planning tools to secure that the emergency business works well for society. When we get the new regions through the Saab acquisitions, and I've met many of them, they have the same need. That means cross-selling between our current components that does something extra for the customers that has Saab SAFE platform in production — that is a typical thing that is a cross-selling because it's inside the same value chain, and it will help people make a better total business on the customer side and use their resources much better. That is a typical value for the customer and a value to us. To sell the larger stack, like the Saab SAFE or the big Cordcom system that we have in other countries in Europe, to sell those adds to together — that is not what we aim to do.
We make sure those complementary stacks are doing the right thing for society, and after that we integrate them. On cross-selling, some of it matters, and some of it isn't usually what we're aiming for.
Thanks, Sverre. There are two more questions still in the queue, but we've got time for another couple as well, so if anything is on your mind, just type your question in and we'll get to it. I'll take the first one, or rather the second-to-last one, and it's about FX. "Congrats on the strong Q2." Thank you. "How large was the FX impact on the 9% organic growth?" What we said is that you can see organic growth in constant currency at 9%, while reported growth is 5%, so that leaves roughly 4% coming from FX headwinds. In numbers, revenue would have been 5 million more had currency stayed constant and unchanged from the second quarter of 2025. On the cost side, the impact came to approximately 3.5 million. EBITDA would have been about 1.5 million higher in constant currency. The margin, more or less unchanged. Okay. If no further questions come in during this one, it will be the last question. Again, while Sverre is answering this, feel free to type in another one, and we'll attend to it. The last question comes from Sivert Helgheim: "You mentioned that AI tools are making your development team significantly more efficient.
So, Sverre, does that mean AI is lowering how much more we need to grow FTE? We noticed FTE came in at 249 — actually lower, it went down this quarter. Could revenue get to that 28% to 32% margin target in '27 without a matching rise in FTEs?" Yes.
Affirmative on that final point, though naturally there are substantial distinctions across these business units. There's no one-size-fits-all response for all of it. Mainly, regarding our forward plan, as you can observe, when we now lift revenue on the strength of the acquisitions completed, and we factor in our FTE count, along with the guidance we've provided — the 28% to 32% for next year — we're holding to that without any need to raise that figure, without needing to make significant changes to our FTE numbers. I believe it's reasonable to state that AI serves as the primary mechanism ensuring we can be efficient and more efficient than was the case a year ago. I additionally note that a great deal of the administrative extra work we've carried out — in areas such as testing and documentation, for example — stands to become far more efficient. Overall, I'd say the FTE count is in place and forms part of the guidance regarding our top line and our EBITDA guidance of 28% to 32% for '27 as well.
Thanks, Sverre. This comes from Hjalmar as the final question. He asks: "If you combine personnel cost with capitalized development, cost per employee was up roughly 7% in Q1 and 8% in Q2. What's driving such a rapid rise, and given the stronger NOK, with the underlying local currency increase even higher, how should we think about that going forward?" I think there are two things worth saying here. First, keep in mind that the cost we record and present for a quarter is really the total cost for that quarter, all-inclusive, while the personnel number is the headcount at quarter-end. That may not represent the actual FTEs present during that quarter. This creates some statistical noise. Second, if you look back a number of years, we had the Filipino employees, and they naturally carried a lower cost per employee. I think what we should focus on is that it's more important to see that selling personnel makes up a smaller part of total cost, as we have planned. Our target is COGS 5%, selling personnel 50%, and other costs, 15% or below. We are approaching that target, so that is really the metric we focus on.
I'll hold off on any further questions, simply because there's a delay between when you enter your question and when it shows up on my screen — I wait a couple of seconds, then refresh my screen. Okay. No, okay, time to wrap things up. It looks like there are no additional questions. We hope you've enjoyed this presentation. Please join us again on the 18th of November, when we'll present the results for the third quarter of 2026. Until then, take care, may God bless Dolly Parton, and stay safe.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Omda AS transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Omda AS earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.